Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved prognostic survival models for pediatric medulloblastoma using high dimensional gene expression data.

BMC medical genomics·2026
Same author

Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR.

Molecular diagnosis & therapy·2026
Same author

Identifying Risk Factors for Readmission amongst Unhoused Burn Patients.

Journal of burn care & research : official publication of the American Burn Association·2026
Same author

An integrated human immunoglobulin germline resource linking allele diversity to expressed repertoire structure.

bioRxiv : the preprint server for biology·2026
Same author

Mesenchymal transitions reduce lamin A expression and nuclear stiffness to enhance confined migration in glioblastoma.

Scientific reports·2026
Same author

Editorial: The Critical Role of Surgery for Local Disease Control and Nodal Assessment in Merkel Cell Carcinoma.

Annals of surgical oncology·2026

Related Experiment Video

Updated: Jun 15, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.6K

The Correlation between Plasma Circulating Tumor DNA and Radiographic Tumor Burden.

Evan M Alexander1, Hunter A Miller1, Michael E Egger2

  • 1Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, Kentucky.

The Journal of Molecular Diagnostics : JMD
|August 24, 2024
PubMed
Summary
This summary is machine-generated.

Integrating plasma circulating tumor DNA (ctDNA) with traditional methods offers a path toward precision medicine. Understanding tumor growth

More Related Videos

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

544

Related Experiment Videos

Last Updated: Jun 15, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.6K
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

544

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Cancer Biomarkers

Background:

  • Conventional biomarkers and imaging monitor cancer but have limitations.
  • Plasma circulating tumor DNA (ctDNA) analysis offers complementary insights.
  • Integrating these methods is key for precision medicine in oncology.

Purpose of the Study:

  • To explore the relationship between tumor growth characteristics and plasma ctDNA concentrations.
  • To provide a perspective on interpreting ctDNA in conjunction with radiographic tumor burden assessments.
  • To highlight the potential of ctDNA as a complementary biomarker in cancer management.

Main Methods:

  • Review of current understanding of tumor growth dynamics.
  • Analysis of plasma ctDNA release from dying tumor cells.
  • Correlation assessment between plasma ctDNA levels and radiographic tumor burden.

Main Results:

  • Plasma ctDNA concentrations correlate with tumor burden, but this association is often weak and variable.
  • Fundamental tumor growth characteristics influence plasma ctDNA levels.
  • Interpretation of longitudinal ctDNA requires consideration of tumor burden variability.

Conclusions:

  • Plasma ctDNA is a valuable tool for monitoring cancer therapy response.
  • Further understanding of tumor biology is needed to optimize ctDNA interpretation.
  • Integrating ctDNA with conventional methods enhances precision cancer care.